Correction | The Medical Letter Inc.

The Medical Letter on Drugs and Therapeutics

FROM
ISSUE

1725

March 31, 2025

View Complete Issue Table of Contents 2019

Correction

Download PDF: US English

Show Related Terms Hide Related Terms

Take CME Exam

View Complete Issue

Send Article Feedback

Med Lett Drugs Ther. 2025 Mar 31;67(1725):56 doi:10.58347/tml.2025.1725d

Disclosures

Objective(s)

Select a term to see related articles Alyftrek cystic fibrosis deutivacaftor elexacaftor ivacaftor tezacaftor Trikafta Vanzacaftor

In our recent article on the combination of vanzacaftor, tezacaftor, and deutivacaftor (Alyftrek) for cystic fibrosis (Med Lett Drugs Ther 2025; 67:41), Table 3 misstated the formulations and dosage of the combination of elexacaftor, tezacaftor, and ivacaftor (Trikafta).

The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

This article has been freely provided.